Investing.com -- Medtronic plc reported third-quarter fiscal 2025 earnings that beat analyst estimates, while revenue fell short of expectations. The medical device maker reiterated its full-year guidance as it sees continued strength in key segments.
Medtronic (NYSE:MDT) posted adjusted earnings per share of $1.39 for the quarter ended January 24, 2025, surpassing the analyst consensus of $1.36. Revenue came in at $8.29 billion, slightly below the $8.33 billion analysts had forecast. The company's stock edged down 0.33% following the results.
Revenue grew 2.5% year-over-year, as reported, and 4.1% on an organic basis. The Cardiovascular portfolio saw 5% organic growth, driven by strong performance in cardiac ablation solutions and structural heart products. The Neuroscience segment posted 5.2% organic growth, with double-digit increases in neuromodulation.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha, Medtronic chairman and CEO.
The company's Diabetes segment showed notable improvement, with revenue increasing 10.4% organically. This was attributed to the continued adoption of the MiniMed 780G automated insulin delivery system in the U.S. and increasing continuous glucose monitoring attachment rates internationally.
Medtronic reiterated its fiscal 2025 guidance, expecting organic revenue growth of 4.75% to 5% and adjusted EPS between $5.44 and $5.50. This outlook aligns with the current analyst consensus of $5.45 per share.
The company highlighted progress in key growth areas, including the rapid adoption of its pulsed field ablation systems and the expected Medicare coverage for renal denervation in treating hypertension by October 2025.
Related Articles
Medtronic Q3 earnings beat estimates, revenue misses
Ugandan army enters eastern Congolese city to halt militia violence
U.S. paper industry urges Trump to negotiate deforestation-free status with EU
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。